COMPARISON OF INTRALESIONAL BOTULINUM TOXIN A AND TRIAMCINOLONE ACETONIDE FOR TREATMENT OF HYPERTROPHIC SCARS AND KELOID

COMPARISON OF INTRALESIONAL BOTULINUM TOXIN A AND TRIAMCINOLONE ACETONIDE FOR TREATMENT OF HYPERTROPHIC SCARS AND KELOID-A SPLIT SCAR INTERVENTIONAL RANDOMIZED CONTROL TRIAL - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/108943

Enrollment

Registered

2026-04-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecified

Interventions

Intervention1: Botulinum toxin A: Use of botulinum toxin A in treatment for hypertrophic scars and keloid will be injected after randomisation of 4-5IU/cm2 every month without exceeding 50IU in one se

Eligibility

Inclusion criteria

Inclusion criteria: All who are willing to give informed written consent

Exclusion criteria

Exclusion criteria: Pregnancy Patients who are breast feeding Skin lesions or infection at the site Any neuromuscular disease Any coagulopathy or is on anticoagulant

Design outcomes

Primary

Measure	Time frame
Improvement in scar texture,colour,and size across 3 sittingsTimepoint: Assessment is done at baseline then at every 3 weeks then final assessment at 12 weeks	—

Secondary

Measure	Time frame
Lack of improvement at 3 weeksTimepoint: 3 weeks	—

Countries

India

Contacts

Public ContactDR PRATIK GAHALAUT

SHRI RAM MURTI SMARAK,INSTITUE OF MEDICAL SCIENCES,DEPARTMENT OF DERMATOLOGY,ROOM 103

drpratikg@rediffmail.com9319758004

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026